[{"id":"6c31d924-416a-4fac-90f3-4e9e04970c2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04708470","created_at":"2021-01-19T20:51:59.772Z","updated_at":"2025-02-25T12:27:53.092Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers","source_id_and_acronym":"NCT04708470","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC"],"overall_status":"Recruiting","enrollment":" Enrollment 107","initiation":"Initiation: 10/05/2021","start_date":" 10/05/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-24"},{"id":"c5926a3c-11fc-4d8b-a13e-2af41702c630","acronym":"","url":"https://clinicaltrials.gov/study/NCT03866382","created_at":"2021-01-18T19:04:09.999Z","updated_at":"2025-02-25T12:37:16.517Z","phase":"Phase 2","brief_title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","source_id_and_acronym":"NCT03866382","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":"","alterations":" ","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 314","initiation":"Initiation: 05/13/2019","start_date":" 05/13/2019","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-24"},{"id":"1bb11f50-7b59-4eb4-901f-d7b6ac9b157d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04287868","created_at":"2021-01-18T20:48:45.296Z","updated_at":"2025-02-25T14:07:41.725Z","phase":"Phase 1/2","brief_title":"Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies","source_id_and_acronym":"NCT04287868","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CDKN2A • CD4","pipe":" | ","alterations":" PD-L1 negative","tags":["PD-L1 • CDKN2A • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • Versamune HPV • PDS01ADC"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 06/09/2020","start_date":" 06/09/2020","primary_txt":" Primary completion: 07/26/2022","primary_completion_date":" 07/26/2022","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2025-02-19"},{"id":"9c0791f2-df06-44ae-99f3-11a3ceff187a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02496208","created_at":"2021-01-18T12:02:15.721Z","updated_at":"2025-02-25T15:10:16.692Z","phase":"Phase 1","brief_title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","source_id_and_acronym":"NCT02496208","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 07/22/2015","start_date":" 07/22/2015","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-13"},{"id":"611fb533-b8fd-4219-b354-66257bca25a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04491942","created_at":"2021-01-18T21:34:47.482Z","updated_at":"2025-02-25T15:26:28.507Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer","source_id_and_acronym":"NCT04491942","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • elimusertib (BAY 1895344) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/25/2021","start_date":" 08/25/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-10"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"7f32c6ae-db00-48e3-960e-6cced44274a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05973487","created_at":"2023-08-03T15:09:34.671Z","updated_at":"2024-07-02T16:34:25.733Z","phase":"Phase 1","brief_title":"A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors","source_id_and_acronym":"NCT05973487","lead_sponsor":"TScan Therapeutics, Inc.","biomarkers":" HLA-A • PRAME • HLA-C","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A • PRAME • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e T-Plex-200-A0201/204-A0201 • TSC-200-A0201 • TSC-204-A0201 • TSC-204-C0702"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/06/2024","start_date":" 05/06/2024","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2024-06-14"},{"id":"cd2f0c6b-9287-4ecc-b80c-c18fadf4071e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03074513","created_at":"2021-01-19T13:46:53.660Z","updated_at":"2024-07-02T16:35:03.337Z","phase":"Phase 2","brief_title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","source_id_and_acronym":"NCT03074513","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 03/03/2017","start_date":" 03/03/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-05-16"},{"id":"9c246bac-2a05-4be1-9b1f-a7e2e819e603","acronym":"AcSé","url":"https://clinicaltrials.gov/study/NCT03012581","created_at":"2021-01-17T17:45:03.399Z","updated_at":"2025-02-25T14:37:06.018Z","phase":"Phase 2","brief_title":"Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types","source_id_and_acronym":"NCT03012581 - AcSé","lead_sponsor":"UNICANCER","biomarkers":" MSI • POLE","pipe":" | ","alterations":" POLE mutation","tags":["MSI • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 269","initiation":"Initiation: 06/16/2017","start_date":" 06/16/2017","primary_txt":" Primary completion: 12/22/2022","primary_completion_date":" 12/22/2022","study_txt":" Completion: 11/11/2023","study_completion_date":" 11/11/2023","last_update_posted":"2024-02-28"},{"id":"55c21f83-a0e4-4e9b-947b-7ac8365bc89c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05787535","created_at":"2023-03-28T14:05:07.469Z","updated_at":"2024-07-02T16:35:21.209Z","phase":"Phase 1","brief_title":"HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor","source_id_and_acronym":"NCT05787535","lead_sponsor":"HRYZ Biotech Co.","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • HRYZ-T101"],"overall_status":"Recruiting","enrollment":" Enrollment 17","initiation":"Initiation: 03/21/2023","start_date":" 03/21/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-02-02"},{"id":"ef8056a0-9ebe-4f7d-a6ed-854f7c1cbfe5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05952947","created_at":"2023-07-20T14:08:58.725Z","updated_at":"2024-07-02T16:35:21.083Z","phase":"Phase 1","brief_title":"HRYZ-T101 Injection for HPV18 Positive Solid Tumor","source_id_and_acronym":"NCT05952947","lead_sponsor":"HRYZ Biotech Co.","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • HRYZ-T101"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 11/01/2023","start_date":" 11/01/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2024-02-02"},{"id":"2365a87d-8e35-400d-9a3b-2c370f444652","acronym":"20-C-0104","url":"https://clinicaltrials.gov/study/NCT04432597","created_at":"2021-01-29T07:20:51.032Z","updated_at":"2024-07-02T16:35:28.048Z","phase":"Phase 1/2","brief_title":"HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers","source_id_and_acronym":"NCT04432597 - 20-C-0104","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" TILs","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824) • PRGN-2009"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 08/11/2020","start_date":" 08/11/2020","primary_txt":" Primary completion: 11/22/2022","primary_completion_date":" 11/22/2022","study_txt":" Completion: 11/20/2025","study_completion_date":" 11/20/2025","last_update_posted":"2023-11-27"},{"id":"fab296e5-5776-4c85-9ae1-37929f5d2dea","acronym":"","url":"https://clinicaltrials.gov/study/NCT05686226","created_at":"2023-01-17T14:59:13.286Z","updated_at":"2024-07-02T16:35:33.810Z","phase":"Phase 2","brief_title":"E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers","source_id_and_acronym":"NCT05686226","lead_sponsor":"Christian Hinrichs","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • E7 TCR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/07/2023","start_date":" 03/07/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-10-12"},{"id":"6b12518b-80ef-430a-abf4-75afc134a955","acronym":"LATENT","url":"https://clinicaltrials.gov/study/NCT03357757","created_at":"2021-01-18T16:34:26.903Z","updated_at":"2024-07-02T16:35:33.916Z","phase":"Phase 2","brief_title":"Avelumab With Valproic Acid in Virus-associated Cancer","source_id_and_acronym":"NCT03357757 - LATENT","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" HSP90AA1","pipe":" | ","alterations":" TILs","tags":["HSP90AA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 02/07/2018","start_date":" 02/07/2018","primary_txt":" Primary completion: 03/30/2022","primary_completion_date":" 03/30/2022","study_txt":" Completion: 02/26/2027","study_completion_date":" 02/26/2027","last_update_posted":"2023-10-11"},{"id":"cd9c68a8-062c-418a-8a7a-3f467abc3209","acronym":"","url":"https://clinicaltrials.gov/study/NCT05639972","created_at":"2022-12-07T16:57:48.136Z","updated_at":"2024-07-02T16:35:33.860Z","phase":"Phase 1/2","brief_title":"E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers","source_id_and_acronym":"NCT05639972","lead_sponsor":"Christian Hinrichs","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Proleukin (aldesleukin) • E7 TCR cells • E7 TCR-T"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 06/12/2024","start_date":" 06/12/2024","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-10-11"},{"id":"a66ace18-adea-483f-af22-5a5f76e11504","acronym":"PULSE","url":"https://clinicaltrials.gov/study/NCT03774901","created_at":"2021-01-29T07:18:27.321Z","updated_at":"2024-07-02T16:35:49.919Z","phase":"Phase 2","brief_title":"Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma","source_id_and_acronym":"NCT03774901 - PULSE","lead_sponsor":"Centre Hospitalier Universitaire de Besancon","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Bavencio (avelumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/12/2019","start_date":" 03/12/2019","primary_txt":" Primary completion: 09/22/2024","primary_completion_date":" 09/22/2024","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2023-04-21"},{"id":"23090ad0-12d2-47eb-b8d8-dc2a255c3aad","acronym":"DUET-4","url":"https://clinicaltrials.gov/study/NCT03849469","created_at":"2021-01-18T18:59:59.498Z","updated_at":"2024-07-02T16:35:51.893Z","phase":"Phase 1","brief_title":"A Study of XmAb®22841 Monotherapy \u0026 in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors","source_id_and_acronym":"NCT03849469 - DUET-4","lead_sponsor":"Xencor, Inc.","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • bavunalimab (XmAb22841)"],"overall_status":"Completed","enrollment":" Enrollment 78","initiation":"Initiation: 05/29/2019","start_date":" 05/29/2019","primary_txt":" Primary completion: 02/16/2023","primary_completion_date":" 02/16/2023","study_txt":" Completion: 02/16/2023","study_completion_date":" 02/16/2023","last_update_posted":"2023-03-30"},{"id":"8a9b9049-bc28-43c5-9df1-3fa9583037fd","acronym":"18-C-0056","url":"https://clinicaltrials.gov/study/NCT03427411","created_at":"2021-01-29T07:16:56.930Z","updated_at":"2024-07-02T16:35:52.157Z","phase":"Phase 2","brief_title":"M7824 in Subjects With HPV Associated Malignancies","source_id_and_acronym":"NCT03427411 - 18-C-0056","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bintrafusp alfa (M7824)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 02/27/2018","start_date":" 02/27/2018","primary_txt":" Primary completion: 02/02/2021","primary_completion_date":" 02/02/2021","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2023-03-28"},{"id":"fa288c29-592d-4dfb-ba55-267713dd3131","acronym":"DUET-2","url":"https://clinicaltrials.gov/study/NCT03517488","created_at":"2021-01-18T17:18:50.722Z","updated_at":"2024-07-02T16:35:59.763Z","phase":"Phase 1","brief_title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","source_id_and_acronym":"NCT03517488 - DUET-2","lead_sponsor":"Xencor, Inc.","biomarkers":" HER-2 • ER • PGR • MSI","pipe":" | ","alterations":" MSI-H/dMMR • HER-2 negative","tags":["HER-2 • ER • PGR • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Completed","enrollment":" Enrollment 150","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 09/06/2022","study_completion_date":" 09/06/2022","last_update_posted":"2022-12-01"},{"id":"65fc83f2-6b27-470e-9e3a-58d6f9d2a044","acronym":"INFLUENCE","url":"https://clinicaltrials.gov/study/NCT04574427","created_at":"2021-01-18T21:50:25.975Z","updated_at":"2024-07-02T16:36:02.223Z","phase":"","brief_title":"INtra-operative Evaluation of a Novel FLUorescENt C-mEt Tracer in Penile and Tongue","source_id_and_acronym":"NCT04574427 - INFLUENCE","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" MET","pipe":" | ","alterations":" MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET expression"],"overall_status":"Completed","enrollment":" Enrollment 5","initiation":"Initiation: 11/13/2019","start_date":" 11/13/2019","primary_txt":" Primary completion: 11/13/2020","primary_completion_date":" 11/13/2020","study_txt":" Completion: 11/14/2020","study_completion_date":" 11/14/2020","last_update_posted":"2022-10-19"},{"id":"4c23fea7-185d-4aea-b8bc-904da5a38f96","acronym":"","url":"https://clinicaltrials.gov/study/NCT03221400","created_at":"2021-01-18T15:53:56.456Z","updated_at":"2024-07-02T16:36:16.953Z","phase":"Phase 1/2","brief_title":"PEN-866 in Patients With Advanced Solid Malignancies","source_id_and_acronym":"NCT03221400","lead_sponsor":"Tarveda Therapeutics","biomarkers":" HSP90AA1","pipe":"","alterations":" ","tags":["HSP90AA1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Zejula (niraparib) • irinotecan • leucovorin calcium • locnartecan (PEN-866)"],"overall_status":"Recruiting","enrollment":" Enrollment 340","initiation":"Initiation: 08/29/2017","start_date":" 08/29/2017","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 06/01/2023","study_completion_date":" 06/01/2023","last_update_posted":"2022-02-17"},{"id":"97e099ff-5286-4e2a-86a3-91ea5e73a0b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03439085","created_at":"2021-01-29T07:16:58.643Z","updated_at":"2024-07-02T16:36:17.195Z","phase":"Phase 2","brief_title":"DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers","source_id_and_acronym":"NCT03439085","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • rocakinogene sifuplasmid (INO-9012) • INO-3112"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 11/14/2018","start_date":" 11/14/2018","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2022-02-14"},{"id":"030f7cf9-f041-43c6-bc9e-83ba6c0b745e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01209325","created_at":"2021-01-29T07:01:10.122Z","updated_at":"2025-02-25T16:00:52.076Z","phase":"Phase 2","brief_title":"Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males","source_id_and_acronym":"NCT01209325","lead_sponsor":"AIDS Malignancy Consortium","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"],"overall_status":"Completed","enrollment":" Enrollment 149","initiation":"Initiation: 06/28/2011","start_date":" 06/28/2011","primary_txt":" Primary completion: 12/12/2017","primary_completion_date":" 12/12/2017","study_txt":" Completion: 12/12/2017","study_completion_date":" 12/12/2017","last_update_posted":"2020-08-11"},{"id":"4f75b0a7-7178-47a9-b387-b0e643dacaa7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02280811","created_at":"2021-01-18T10:44:29.678Z","updated_at":"2024-07-02T16:37:18.118Z","phase":"Phase 1/2","brief_title":"T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers","source_id_and_acronym":"NCT02280811","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • E6 TCR • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 10/14/2014","start_date":" 10/14/2014","primary_txt":" Primary completion: 06/28/2016","primary_completion_date":" 06/28/2016","study_txt":" Completion: 06/28/2016","study_completion_date":" 06/28/2016","last_update_posted":"2017-09-06"}]